Article info
Neurodegeneration
Original research
GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance
- Correspondence to Dr Eino Solje, Institute of Clinical Medicine, Department of Neurology, University of Eastern Finland, Kuopio FI-70211, Finland; eino.solje{at}uef.fi
Citation
GFAP as a biomarker in frontotemporal dementia and primary psychiatric disorders: diagnostic and prognostic performance
Publication history
- Received February 25, 2021
- Accepted June 12, 2021
- First published June 29, 2021.
Online issue publication
January 07, 2022
Article Versions
- Previous version (7 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.